Clareo Health | BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia
BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Florida
With
Food and Drug Administration (FDA)
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Admission to the ICU with severe pneumonia (IDSA/ATS 2016/2019): presence of signs, symptoms and confirmatory chest imaging consistent with pneumonia (e.g. fever, cough and pulmonary infiltrate by chest radiograph)
Age ≥18 years
Positive respiratory culture (with or without an initial positive rapid identification test and/or Gram stain) for Gram-negative bacteria including, but not limited to, P. aeruginosa, K. pneumoniae, E. coli, S. marcescens, H. influenzae, Enterobacter spp., M. catarrhalis, A. baumannii, Achromobacter spp., P. mirabilis, and/or B. cepacia
Received within the last 72 hours or will receive meropenem, cefepime, or piperacillin/tazobactam therapy
You may not be if
Pregnancy
Prisoners
Allergy to the beta-lactams to be administered in this study
On renal replacement therapy at the time of randomization
Baseline culture resistant to the beta-lactams in the study
